10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. Its integrated solutions include single cell ...

The market expects 10x Genomics (TXG) to deliver a year-over-year increase in earnings on lower revenues when it reports results for the quarter ended December 2024. This widely-known consensus ...

10x Genomics excels in single-cell and spatial technologies but faces significant challenges. Despite an EPS beat, revenue fell 1% due to sales disruption and competitive pricing. The company's ...

These factors together underpin the positive long-term outlook for 10x Genomics. Souda covers the Healthcare sector, focusing on stocks such as Revvity, Exact Sciences, and Natera. According to ...

EST Cathie Wood’s ARK Investment buys 77.6K shares of 10x Genomics (TXG) today Published first on TheFly – the ultimate source for ...

CEO Serge Saxonov, PhD, says provider of single cell, spatial, and in situ instruments expects to see benefits from sales ...

Furthermore, the services segment experienced robust year-over-year and quarter-over-quarter growth, showcasing 10x Genomics’s ability to expand its offerings and enhance its market position.

X Genomics Inc (TXG) stock saw a decline, ending the day at $14.41 which represents a decrease of $-0.04 or -0.28% from the prior close of $14.45. The stock opened at $14.25 and touched a low of ...

10x Genomics delivers powerful, reliable tools that fuel scientific discoveries and drive exponential progress to master biology and to advance human health. Cited in more than 7,000 research papers, ...